342600-79-7

Upstream product

• 138603-50-6 cis-4-amino-3-chromanol 
• 597563-62-7 (2R,4S)-2-Benzyl-4-(tert-butyl-dimethyl-silanyloxy)-5-[(S)-4-[1-methyl-1-(5-pyridin-4-yl-furan-2-yl)-ethyl]-2-(2,2,2-trifluoro-ethylcarbamoyl)-piperazin-1-yl]-pentanoic acid 
• 1120-87-2 4-bromopyridin 
• 597563-59-2 (S)-4-[1-Methyl-1-(5-pyridin-4-yl-furan-2-yl)-ethyl]-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide 
• 342600-77-5 (S)-4-[Cyano-methyl-(5-pyridin-4-yl-furan-2-yl)-methyl]-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide 
• 342600-76-4 (S)-4-[Cyano-methyl-(5-pyridin-4-yl-furan-2-yl)-methyl]-2-(2,2,2-trifluoro-ethylcarbamoyl)-piperazine-1-carboxylic acid allyl ester 
• 342600-78-6 (S)-1-((2S,4R)-4-Benzyl-5-oxo-tetrahydro-furan-2-ylmethyl)-4-[1-methyl-1-(5-pyridin-4-yl-furan-2-yl)-ethyl]-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide 

Relevant academic research and scientific papers

HIV protease inhibitors with picomolar potency against PI-resistant HIV-1 by extension of the P3 substituent

A biaryl pyridylfuran P3 substituent on the hydroxyethylene isostere scaffold affords HIV protease inhibitors (PI's) with picomolar (IC50) potency against the protease enzymes from PI-resistant HIV-1 strains. Inclusion of a gem-dimethyl substituent afforded compound 3 with 100% oral bioavailability (dogs) and more than double the t1/2 of indinavir. Inhibition of multiple P450 isoforms is dependent on the regiochemistry of the pyridyl nitrogen in these compounds.

Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides and uses thereof

γ-Hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamide compounds are inhibitors of HIV protease and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described. These compounds are effective against HIV viral mutants which are resistant to HIV protease inhibitors currently used for treating AIDS and HIV infection.